JP2015521642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521642A5 JP2015521642A5 JP2015519034A JP2015519034A JP2015521642A5 JP 2015521642 A5 JP2015521642 A5 JP 2015521642A5 JP 2015519034 A JP2015519034 A JP 2015519034A JP 2015519034 A JP2015519034 A JP 2015519034A JP 2015521642 A5 JP2015521642 A5 JP 2015521642A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- disorder
- disease
- pharmaceutically acceptable
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 claims 11
- 230000036407 pain Effects 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 230000036541 health Effects 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- LUEYUHCBBXWTQT-UHFFFAOYSA-N 4-phenyl-2h-triazole Chemical class C1=NNN=C1C1=CC=CC=C1 LUEYUHCBBXWTQT-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- RXSRUWRCDDEWSN-UHFFFAOYSA-N 1-[6-[[5-(2-fluorophenyl)-3-methyltriazol-4-yl]methoxy]pyridin-3-yl]imidazole-4-carbonitrile Chemical compound CN1N=NC(C=2C(=CC=CC=2)F)=C1COC(N=C1)=CC=C1N1C=NC(C#N)=C1 RXSRUWRCDDEWSN-UHFFFAOYSA-N 0.000 claims 1
- NWVGXXPWOYZODV-UHFFFAOYSA-N 1h-imidazole-5-carbonitrile Chemical compound N#CC1=CN=CN1 NWVGXXPWOYZODV-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 206010015958 Eye pain Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010072132 Fracture pain Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims 1
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007278 cognition impairment Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000003349 osteoarthritic effect Effects 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664287P | 2012-06-26 | 2012-06-26 | |
| DKPA201270368 | 2012-06-26 | ||
| DKPA201270368 | 2012-06-26 | ||
| US61/664,287 | 2012-06-26 | ||
| PCT/EP2013/063193 WO2014001281A1 (en) | 2012-06-26 | 2013-06-25 | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521642A JP2015521642A (ja) | 2015-07-30 |
| JP2015521642A5 true JP2015521642A5 (enExample) | 2016-08-12 |
| JP6224097B2 JP6224097B2 (ja) | 2017-11-01 |
Family
ID=49782299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519034A Expired - Fee Related JP6224097B2 (ja) | 2012-06-26 | 2013-06-25 | フェニルトリアゾール誘導体及びｇａｂａａ受受容体複合体を調節するための該フェニルトリアゾール誘導体の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9206160B2 (enExample) |
| EP (1) | EP2877463B1 (enExample) |
| JP (1) | JP6224097B2 (enExample) |
| KR (1) | KR20150033678A (enExample) |
| CN (1) | CN104411699B (enExample) |
| AU (1) | AU2013283487C1 (enExample) |
| CA (1) | CA2876778A1 (enExample) |
| IL (1) | IL236041A (enExample) |
| MX (1) | MX357504B (enExample) |
| WO (1) | WO2014001281A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015140081A1 (en) * | 2014-03-18 | 2015-09-24 | Algiax Pharmaceuticals Gmbh | 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| EP3858965B1 (en) * | 2020-01-28 | 2022-05-11 | The Procter & Gamble Company | Cleaning product |
| US12649738B2 (en) | 2020-03-26 | 2026-06-09 | Richter Gedeon Nyrt. | 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators |
| TWI901650B (zh) * | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| TWI915398B (zh) * | 2020-08-05 | 2026-02-21 | 丹麥商薩尼奧納有限責任公司 | 二氟甲基-吡啶-2-基三唑 |
| IL310708A (en) * | 2021-08-12 | 2024-04-01 | Shanghai Simr Biotechnology Co Ltd | The history of converted triazole, a method for its preparation, its pharmaceutical preparation and its use |
| WO2024023268A1 (en) | 2022-07-29 | 2024-02-01 | F. Hoffmann-La Roche Ag | Characterisation of neurological dysfunction |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2314401A1 (en) * | 1997-12-22 | 1999-07-01 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
| JP2009508905A (ja) | 2005-09-19 | 2009-03-05 | エフ．ホフマン−ラ ロシュ アーゲー | ＧＡＢＡＡα５逆アゴニストとしてのイソオキサゾロ誘導体 |
| CN101277952B (zh) | 2005-10-11 | 2011-09-28 | 弗·哈夫曼-拉罗切有限公司 | 异*唑衍生物 |
| DE602006014185D1 (de) | 2005-11-09 | 2010-06-17 | Hoffmann La Roche | 3-arylisoxazol-4-carbonylbenzofuranderivative |
| RU2426731C2 (ru) | 2005-12-23 | 2011-08-20 | Ф. Хоффманн-Ля Рош Аг | Производные арил-изоксазоло-4-ил-оксадиазола |
| PL1968973T3 (pl) | 2005-12-27 | 2012-03-30 | Hoffmann La Roche | Pochodne aryloizoksazol-4-iloimidazolu |
| ATE537171T1 (de) | 2005-12-27 | 2011-12-15 | Hoffmann La Roche | Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e |
| KR101119365B1 (ko) | 2006-05-31 | 2012-03-07 | 에프. 호프만-라 로슈 아게 | 아릴-4-에틴일-아이속사졸 유도체 |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| CN101965344B (zh) | 2007-06-22 | 2013-03-06 | 弗·哈夫曼-拉罗切有限公司 | 异*唑-咪唑衍生物 |
| JP5301557B2 (ja) * | 2007-12-04 | 2013-09-25 | エフ．ホフマン−ラ ロシュ アーゲー | イソオキサゾロ−ピリジン誘導体 |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| US7618973B2 (en) | 2007-12-04 | 2009-11-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyrazine derivatives |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
| US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| US8227461B2 (en) | 2009-04-30 | 2012-07-24 | Hoffmann-La Roche Inc. | Isoxazoles |
| ES2601181T3 (es) | 2009-05-05 | 2017-02-14 | F. Hoffmann-La Roche Ag | Derivados de isoxazol-tiazol como agonistas inversos del receptor GABA A para su uso en el tratamiento de trastornos cognitivos |
| US8415379B2 (en) | 2009-05-05 | 2013-04-09 | Hoffmann-La Roche Inc. | Pyridines |
| BRPI1014454A2 (pt) | 2009-05-05 | 2016-04-05 | Hoffmann La Roche | derivados de isoxazol-pirazol |
| BRPI1013762A2 (pt) | 2009-05-05 | 2015-08-25 | Hoffmann La Roche | "derivados isoxazol-piridazina" |
| KR101354416B1 (ko) | 2009-05-07 | 2014-02-19 | 에프. 호프만-라 로슈 아게 | 감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체 |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| CN103189062B (zh) | 2010-11-05 | 2016-03-23 | 霍夫曼-拉罗奇有限公司 | 活性药物化合物用于治疗中枢神经系统病症的用途 |
| US8742097B2 (en) | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| US8466181B2 (en) | 2010-12-10 | 2013-06-18 | Hoffmann-La Roche Inc. | 1,2,3-triazole-imidazole compounds |
-
2013
- 2013-06-25 MX MX2014014871A patent/MX357504B/es active IP Right Grant
- 2013-06-25 JP JP2015519034A patent/JP6224097B2/ja not_active Expired - Fee Related
- 2013-06-25 KR KR20157001888A patent/KR20150033678A/ko not_active Ceased
- 2013-06-25 CA CA2876778A patent/CA2876778A1/en not_active Abandoned
- 2013-06-25 EP EP13732127.9A patent/EP2877463B1/en not_active Not-in-force
- 2013-06-25 US US14/411,331 patent/US9206160B2/en not_active Expired - Fee Related
- 2013-06-25 CN CN201380033706.1A patent/CN104411699B/zh not_active Expired - Fee Related
- 2013-06-25 AU AU2013283487A patent/AU2013283487C1/en not_active Ceased
- 2013-06-25 WO PCT/EP2013/063193 patent/WO2014001281A1/en not_active Ceased
-
2014
- 2014-12-03 IL IL236041A patent/IL236041A/en not_active IP Right Cessation
-
2015
- 2015-11-16 US US14/942,705 patent/US9931329B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015521643A5 (enExample) | ||
| HRP20201216T1 (hr) | PRIPRAVCI I POSTUPCI ZA LIJEČENJE POREMEĆAJA CNS-a | |
| JP2010529118A5 (enExample) | ||
| JP6933964B2 (ja) | ヘテロアリール化合物およびそれらの使用方法 | |
| CN109963854A (zh) | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2019031502A5 (enExample) | ||
| JP2017524005A5 (enExample) | ||
| JP2021531291A5 (enExample) | ||
| JP2011524850A5 (enExample) | ||
| NO20063381L (no) | CB1 modulatorforbindelser | |
| JP2010502722A5 (enExample) | ||
| JP2013526544A5 (enExample) | ||
| AR079542A1 (es) | Derivados de benzamida sustituidos, proceso para su preparacion y su uso en el tratamiento de enfermedades mediadas por taars. | |
| HRP20090640T1 (hr) | Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida | |
| HRP20180487T1 (hr) | Upotreba flekainida kao anti-koneksinskog sredstva i metoda za potenciranje učinaka psihotropnog lijeka | |
| JP2015514677A5 (enExample) | ||
| JP2016147915A5 (enExample) | ||
| UY37328A (es) | Compuestos diazaheterobicíclicos sustituidos y su uso | |
| JP2012526832A5 (enExample) | ||
| HRP20201405T1 (hr) | Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a | |
| HRP20120876T1 (hr) | Brzo disocirajuä†i antagonisti dopamin 2 receptora | |
| RU2014149123A (ru) | Фенилтриазольное производное и его применение для модуляции ГАМКА-рецепторного комплекса | |
| JP2013538206A5 (enExample) | ||
| RU2011103759A (ru) | Замещенные 6-(1-пиперазинил)-пиридазины в качестве антагонистов 5-нт6 рецептора | |
| JP2019511548A5 (enExample) |